Who are NALIRIFOX plus targeted therapy's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/nalirifox-plus-targeted-therapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

NALIRIFOX plus targeted therapy — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

NALIRIFOX plus targeted therapy (NALIRIFOX plus targeted therapy) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination chemotherapy with targeted therapy. Area: Oncology.

phase 3 Combination chemotherapy with targeted therapy Topoisomerase I, thymidylate synthase, and variable molecular targets depending on targeted therapy partner Oncology Small molecule Live · refreshed every 30 min

Target snapshot

NALIRIFOX plus targeted therapy (NALIRIFOX plus targeted therapy) — Shanghai Zhongshan Hospital. NALIRIFOX is a combination of nal-IRI (irinotecan liposomal) and 5-fluorouracil that inhibits topoisomerase I and nucleotide synthesis, combined with targeted therapy to enhance anti-tumor activity.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
NALIRIFOX plus targeted therapy TARGET	NALIRIFOX plus targeted therapy	Shanghai Zhongshan Hospital	phase 3	Combination chemotherapy with targeted therapy	Topoisomerase I, thymidylate synthase, and variable molecular targets depending on targeted therapy partner

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination chemotherapy with targeted therapy class)

Shanghai Zhongshan Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). NALIRIFOX plus targeted therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/nalirifox-plus-targeted-therapy. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab